These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 22978161)

  • 1. [The modified restriction of amino acids of HVR1, HVR2, HVR5, HVR7 in human adenovirus serotype 3 hexon].
    Zhou ZC; Liang HX; Li T; Zhong TH; Tian XG; Zhou R; Li X
    Bing Du Xue Bao; 2012 Jun; 28(4):372-81. PubMed ID: 22978161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction and characterization of a recombinant human adenovirus type 3 vector containing two foreign neutralizing epitopes in hexon.
    Xue C; Tian X; Li X; Zhou Z; Su X; Zhou R
    Virus Res; 2014 Apr; 183():67-74. PubMed ID: 24518297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and characterization of human adenovirus serotype 3 packaged by serotype 7 hexon.
    Tian X; Su X; Li H; Li X; Zhou Z; Liu W; Zhou R
    Virus Res; 2011 Sep; 160(1-2):214-20. PubMed ID: 21740937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric hexon HVRs protein reflects partial function of adenovirus.
    Yu B; Wang C; Dong J; Zhang M; Zhang H; Wu J; Wu Y; Kong W; Yu X
    Biochem Biophys Res Commun; 2012 May; 421(2):170-6. PubMed ID: 22490664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer.
    Alba R; Bradshaw AC; Parker AL; Bhella D; Waddington SN; Nicklin SA; van Rooijen N; Custers J; Goudsmit J; Barouch DH; McVey JH; Baker AH
    Blood; 2009 Jul; 114(5):965-71. PubMed ID: 19429866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilizing the antigen capsid-incorporation strategy for the development of adenovirus serotype 5-vectored vaccine approaches.
    Gu L; Farrow AL; Krendelchtchikov A; Matthews QL
    J Vis Exp; 2015 May; (99):e52655. PubMed ID: 25993057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of malleability and immunological properties of human adenovirus type 3 hexon hypervariable region 1.
    Zhong T; Li X; Zhou Z; Li T; Tian X; Zhou R
    Arch Virol; 2012 Sep; 157(9):1709-18. PubMed ID: 22669318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic strategy to decrease complement activation with adenoviral therapies.
    Gentile CM; Borovjagin AV; Richter JR; Jani AH; Wu H; Zinn KR; Warram JM
    PLoS One; 2019; 14(4):e0215226. PubMed ID: 31026285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors.
    Bruder JT; Chen P; Semenova E; Thomas CA; Konovalova S; Ekberg G; Ettyreddy D; McVey D; Gall JG; King CR; Brough DE
    J Virol; 2013 Sep; 87(17):9661-71. PubMed ID: 23824800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotype-specific neutralizing antibody epitopes of human adenovirus type 3 (HAdV-3) and HAdV-7 reside in multiple hexon hypervariable regions.
    Qiu H; Li X; Tian X; Zhou Z; Xing K; Li H; Tang N; Liu W; Bai P; Zhou R
    J Virol; 2012 Aug; 86(15):7964-75. PubMed ID: 22623776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
    Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
    Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
    Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
    Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy.
    Short JJ; Rivera AA; Wu H; Walter MR; Yamamoto M; Mathis JM; Curiel DT
    Mol Cancer Ther; 2010 Sep; 9(9):2536-44. PubMed ID: 20736345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circumvention of immunity to the adenovirus major coat protein hexon.
    Roy S; Shirley PS; McClelland A; Kaleko M
    J Virol; 1998 Aug; 72(8):6875-9. PubMed ID: 9658137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus hexon modifications influence in vitro properties of pseudotyped human adenovirus type 5 vectors.
    Solanki M; Zhang W; Jing L; Ehrhardt A
    J Gen Virol; 2016 Jan; 97(1):160-168. PubMed ID: 26519158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues.
    Crawford-Miksza L; Schnurr DP
    J Virol; 1996 Mar; 70(3):1836-44. PubMed ID: 8627708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach.
    Matthews QL; Yang P; Wu Q; Belousova N; Rivera AA; Stoff-Khalili MA; Waehler R; Hsu HC; Li Z; Li J; Mountz JD; Wu H; Curiel DT
    Virol J; 2008 Aug; 5():98. PubMed ID: 18718011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of adenovirus type 7 hexon hypervariable region].
    Takeuchi S; Oshima A; Itoh N; Kitamura N; Uchio E; Aoki K; Ohno S
    Nippon Ganka Gakkai Zasshi; 1998 Sep; 102(9):570-5. PubMed ID: 9785853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using multivalent adenoviral vectors for HIV vaccination.
    Gu L; Li ZC; Krendelchtchikov A; Krendelchtchikova V; Wu H; Matthews QL
    PLoS One; 2013; 8(3):e60347. PubMed ID: 23555957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions.
    Bradley RR; Maxfield LF; Lynch DM; Iampietro MJ; Borducchi EN; Barouch DH
    J Virol; 2012 Jan; 86(2):1267-72. PubMed ID: 22072746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.